Guangzhou Wondfo Biotech Co (300482) Fair Value & Analysis

Healthcare · CN · Market cap 9.8B CNY

Below-average quality, and screening another 69% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (¥6.71). The favourable scenario is already priced in.
• Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 9, 2026.

How to read this chart

60‑month range ¥15.69 – ¥72.94 · fair‑value band ¥4.23 – ¥6.71 · the ¥17.52 price screens above the ¥5.47 fair value. Dashed = 300-day average. As of Jul 9, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Guangzhou Wondfo Biotech Co (300482) currently trades at ¥17.52, while our model-based Fair Value estimate is ¥5.47, implying the stock looks roughly 68.8% overvalued today. The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Guangzhou Wondfo Biotech Co generated revenue of 1.9B CNY at a net margin of -9.0%. Revenue declined 27.3% year over year. It earns a return on equity of -3.0%. The balance sheet holds a net cash position of 243M CNY. Fundamentals as of Jul 9, 2026

Our scenario range runs from ¥4.23 (bear case) to ¥6.71 (bull case); at ¥17.52, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 33% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -69%, 300482 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models (¥8.09) versus Multiples (¥5.39). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, market, sale, and service of vitro diagnostic products in China.

Full company description

Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, market, sale, and service of vitro diagnostic products in China. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious disease, fertility, tumor marker, and sexually transmitted diseases; immunofluorescence platform for detecting cardiac, thyroid, rheumatoid arthritis, sex hormone, anemia, gastroenterology, hypertension, thrombus, tumor, inflammation, diabetes, allergy, respiratory infection, kidney, brain injury, bone metabolism, and infectious disease; and chemiluminescence platform. It also provides semi-automatic blood coagulation analyzer and optical blood coagulation; automatic blood gas biochemical analyzer and blood gas analyzer; molecular diagnostics platform; fully automated pathology straining system; and fully automatic HbAlc analyzer. In addition, the company offers solutions, such as new-generation vitamin D, wondfo CRP campaign, international public health solutions, POCT lab, and COVID-19 total solution. Its products are used in clinical testing, critical illness, chronic disease management, primary care, epidemic monitoring, disaster relief, on-site law enforcement, and family personal health management. The company was founded in 1992 and is based in Guangzhou, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Guangzhou Wondfo Biotech Co reported revenue of ¥2.1B in FY2025 versus ¥3.4B in FY2021, a compound −11.2%/yr. Reported net income was −¥63.0M in FY2025.

300482 screens 69% overvalued. Compare with Abbott Laboratories, →

Peer Group

Medical Devices · 351 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Devices median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.